InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) to Spotlight Concussion Candidate at BIO 2025 and Neurotrauma Symposium
Oragenics (NYSE American: OGEN) announced that Head of Business Development Greg Gironda will present at the 2025 BIO International Convention from June 16–19 in Boston, while the company also attends the 42nd Annual National Neurotrauma Society Symposium from June 15–18 in Philadelphia. The events provide critical platforms to showcase ONP-002, Oragenics’ intranasal neurosteroid candidate for concussion treatment, and to connect with global leaders across neuroscience…